• Curevo

  Participated · Series B · Mar 2025

  Curevo is a clinical-stage biotechnology company focused on developing vaccines with improved tolerability and accessibility. Its lead product, amezosvatein, is a non-mRNA adjuvanted sub-unit vaccine designed to prevent shingles. The company raised $110M in a Series B to accelerate clinical development. Curevo intends to use the funds to extend its Phase 2 program by an additional 640 participants, including adults over age 70, to finalize dose selection ahead of Phase 3. Leadership includes CEO George Simeon, and the financing is accompanied by additions to the board to support late-stage development planning. The company is based in Seattle, WA. Curevo Vaccine is a Seattle-based, clinical-stage biotech focused on developing safe, highly effective subunit vaccines using an adjuvanted platform. Its lead candidate, CRV-101, is an adjuvanted subunit vaccine being evaluated to prevent shingles in older adults and was designed to use a smaller amount of adjuvant to aim for comparable efficacy with fewer side effects. In Phase 1, CRV-101 showed robust humoral and cellular immunogenicity with no grade 3 injection-site reactions and a 1.3% rate of grade 3 systemic side effects. CRV-101 is in a head-to-head Phase 2b trial versus Shingrix®, in which Curevo enrolled 678 patients in six months; topline data were expected in early 2023. The company is also developing a non-live subunit chickenpox vaccine. Financially, Curevo completed a $26 million Series A1 financing and previously raised $86 million in 2022, which company management says extends its cash runway. Curevo Vaccine is a clinical-stage biotech based in Seattle focused on developing safe, highly effective adjuvanted subunit vaccines via its sub-unit vaccine technology platform. Its lead product, CRV-101, is an adjuvanted sub-unit vaccine under investigation to prevent shingles in older adults and is designed to use less adjuvant to aim for similar efficacy with fewer side effects. The company reported encouraging Phase 1 data showing robust humoral and cellular immunogenicity, no grade 3 injection-site side effects, and a 1.3% rate of grade 3 systemic side effects. Curevo is conducting a 678-patient Phase 2b trial intended to compare CRV-101’s immunogenicity and safety profile relative to Shingrix. The firm is also developing a non-live subunit chickenpox vaccine to address unmet needs for more accessible vaccines. Curevo announced a $60 million Series A to fund clinical development through topline data from the Phase 2b trial.

• MiNDCAFE

  Participated · Series B · Feb 2022

  Atommerce operates MiNDCAFE, a mobile app connecting users with mental health professionals via virtual therapy and an employer-focused mental health benefits (EAP) solution. The company also offers an AI chatbot, RONI, launched in December, which supports human professionals by recommending answers and is part of an ecosystem linking patients, experts and AI. With over 1 million app users in South Korea, roughly 100 enterprise clients (including Naver, NHN, Shinhan Investment, Neowiz and Seoul Metropolitan Government), about 200,000 employees using the app via EAPs, and more than 250 specialists, Atommerce has significant traction. Its revenue grew about 1,200% in Q1 2021 versus Q1 2020, and sales have risen an average of 400% annually over the past two years. The company plans to enhance its AI and machine-learning capabilities, invest in digital therapeutics, increase headcount, and expand internationally to Japan in H1 2022 and North America by year-end. Atommerce was founded in 2015 and is headquartered in Seoul.

• Artiva Biotherapeutics

  Participated · Series B · Feb 2021

  Artiva is an oncology-focused biopharmaceutical company building primary allogeneic NK cell therapies optimized for anti-tumor activity and safety. Its platform supports large-scale production and cryopreservation of off-the-shelf NK cell therapies and includes proprietary CAR-NK and NK-specific gene-editing technologies. The pipeline includes AB-101, an ADCC-enhancer NK-cell therapy in a Phase 1/2 trial in combination with rituximab for relapsed or refractory B-cell lymphomas. Its CAR-NK programs include AB-201 (HER2-specific for HER2+ solid tumors) and AB-202 (CD19-specific for B-cell malignancies), with plans to enter clinical trials in 2022 under a master license and option agreement with GC LabCell. Artiva has entered therapeutic collaborations or license agreements with Merck and Affimed and leverages cell-expansion and engineering technology developed by corporate partner GC LabCell. The company is headquartered in San Diego and emphasizes a "manufacturing first" strategy to deliver immediately accessible cell therapies. Artiva is an oncology company focused on developing and commercializing allogeneic, off-the-shelf NK cell and CAR-NK therapies. Its initial pipeline includes AB-101 (a universal NK cell therapy intended for use with monoclonal antibodies), AB-201 (a HER2-specific CAR-NK for HER2+ solid tumors), and AB-202 (a CD19-specific CAR-NK for CD19+ B-cell malignancies). The company emphasizes large-scale production and effective cryopreservation to enable high and repeat dosing, and it leverages a manufacturing and engineering platform optimized for expansion, activation, engineering, and NK-specific gene editing. Artiva has exclusive ex-Asia-Pacific license agreements with GC LabCell covering core manufacturing and CAR technology and an option to license additional research candidates under a Joint Steering Committee. The company plans to enter the clinic this year with AB-101 in combination with an anti-CD20 monoclonal antibody to treat relapsed refractory B-cell lymphoma. Artiva is headquartered in San Diego and will use its new financing to advance its universal NK cell and CAR-NK product candidates.

• Juventas Therapeutics

  Led · Series B · May 2015

  Juventas Therapeutics is focused on developing non-viral gene therapies for advanced cardiovascular diseases, with its lead candidate JVS-100 undergoing evaluation in clinical studies. JVS-100 is being developed under an exclusive license from the Cleveland Clinic. The company was founded in 2007 and is based in Cleveland, Ohio, and is led by president and CEO Rahul Aras, Ph.D. Juventas recently expanded its Board of Directors with the addition of James Boland. Financially, the company secured a financing package comprising equity and debt to support its clinical-stage programs. The financing details indicate a mix of Series B-2 equity and debt with milestone-linked additional capital available. Juventas Therapeutics, founded in 2007 and led by President & CEO Rahul Aras, Ph.D., is a Cleveland, OH-based clinical-stage regenerative medicine company advancing JVS-100, its lead product encoding Stromal cell‑Derived Factor 1 (SDF‑1). JVS-100 has been shown to repair damaged tissue by recruiting circulating stem cells to sites of injury, preventing ongoing cell death, and restoring blood flow. The company closed a $22.2M Series B financing and intends to use the funds to complete ongoing Phase II clinical trials. The Phase II trials are investigating JVS-100 in patients with chronic heart failure and critical limb ischemia, and both trials are actively enrolling. The financing supports continued clinical development of the therapy and associated programs.

• Argos Therapeutics

  Participated · Series E · Nov 2013

  Argos Therapeutics focuses on the development and commercialization of individualized immunotherapies for cancer and infectious diseases. Its most advanced product, Rocapuldencel-T, is being evaluated in a clinical trial for metastatic renal cell carcinoma. The company has a partnership with Hong Kong firm Lummy for Rocapuldencel-T in China and other territories. Argos has faced financial pressure: its stock fell 65 percent in one day in February 2017 and the company has not received FDA approval for any drug since its establishment in 1997. In November 2017 Argos received $1.8 million from TKC Properties selling a building that housed one of the company’s facilities, funds the company said will allow it to last through June. At the time of the filing its stock traded around 16–17 cents per share. Argos Therapeutics develops fully personalized immunotherapies via its Arcelis™ technology, which captures mutated and variant antigens specific to each patient’s disease and is aimed at multiple cancers and infectious diseases. The company’s lead candidate, AGS-003, has initiated a pivotal Phase 3 ADAPT trial for metastatic renal cell carcinoma (mRCC). Argos recently raised additional funding to support that trial and to advance its clinical programs. The company raised an additional $17.5M in Series E financing, bringing total committed Series E funds to $60M. Argos is led by president and CEO Jeff Abbey and is based in Durham, North Carolina. Its AGS-004 candidate recently completed enrollment of a Phase 2b study for HIV. Argos Therapeutics leverages its Arcelis technology platform to develop personalized immunotherapies for the treatment of cancer and infectious diseases. Its lead product candidate, AGS-003, has initiated a pivotal Phase 3 study for metastatic renal cell carcinoma (mRCC). The company also develops AGS-004 for the treatment of HIV and expects Phase 2b data in the first half of 2014. Argos intends to use proceeds from the financing to support the Phase 3 clinical study of AGS-003. In August 2013 the company secured $42.5M in Series E financing, providing near-term capital to advance its clinical programs. Jeff Abbey serves as President and Chief Executive Officer. Argos Therapeutics is a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies using its Arcelis™ technology platform. The Arcelis platform uses biological components from each patient and employs the patient’s dendritic cells to activate an immune response specific to the patient’s disease. The company’s most advanced product candidates are AGS-003 for metastatic renal cell carcinoma (mRCC) and AGS-004 for HIV. Research and development are led by Charles Nicolette, Ph.D., chief scientific officer and vice president of R&D. Argos raised $25M in a Series D financing and intends to use the proceeds to support the planned commencement of its Phase 3 ADAPT study in newly diagnosed mRCC patients in mid-2012.

No current team members are available.